Red flags to diagnose infiltrative cardiomyopathies

Infiltrative cardiomyopathies are a group of diseases characterized by the deposition of abnormal substances in heart tissues, which leads to thickening of the walls or dilation of chambers with a secondary decrease in wall thickness and the development of diastolic, less often systolic, ventricular dysfunction. Most often, these are progressive diseases that, in the absence of adequate therapy, have an unfavorable prognosis. Clinical manifestations of infiltrative cardiac diseases are variable, which often leads to diagnostic difficulties and errors. In most cases, specific laboratory and morphological tests are required to confirm or clarify the diagnosis. Early diagnosis is critical to initiating therapy and improving patient prognosis. This article provides characteristic signs and symptoms, the so-called "red flags", making it possible to suspect infiltrative cardiomyopathies, diagnose them at an early stage and start life-saving therapy.

1. Kushwaha SS, Fallon JT, Fuster V. Restrictive Cardiomyopathy. New England Journal of Medicine. 1997;336:267-76. doi:10.1056/NEJM199701233360407.

2. Seward J, Verzosa G. Infiltrative Cardiovascular Diseases. Cardiomyopathies That Look Alike. Journal of the American College of Cardiology. 2010;55:1769-79. doi:10.1016/j.jacc.2009.12.040.

3. Madan N, Kalra D. Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020;21:181-90. doi:10.31083/j.rcm.2020.02.65.

4. Braunwald E, Zipes DP, Libby P. Heart Disease: A Textbook of Cardiovascular Medicine. Saunders 2001. 2297 p. ISBN: 0721685617.

5. Moiseev VS. Cardiomyopathy and myocarditis. GEOTAR-Media, 2020. 512 p. (In Russ.) ISBN: 978-5-9704-5429-9.

6. Vergaro G, Aimo A, Barison A, et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. European Journal of Preventive Cardiology. 2020;27:1806-15. doi:10.1177/2047487319877708.

7. Moiseev AS, Moiseev SV, Tao EA, et al. Clinical manifestations and outcomes of Fabry disease in 150 adult patients. Clinical pharmacology and therapy. 2021;30:43-51. (In Russ.) doi:10.32756/0869-5490-2021-3-43-51.

8. Weidemann F, Reiser M. Fabry Disease. JACC: Cardiovascular Imaging. 2019;12:1684-5. doi:10.1016/j.jcmg.2018.05.029.

9. Kubaski F, de Oliveira Poswar F, Michelin-Tirelli K, et al. Diagnosis of Mucopolysaccharidoses. Diagnostics (Basel). 2020;10:172. doi:10.3390/diagnostics10030172.

10. Cenacchi G, Papa V, Pegoraro V, et al. Review: Danon disease: Review of natural history and recent advances. Neuropathol Appl Neurobiol. 2020;46:303-22. doi:10.1111/nan.12587.

11. Cook A, Giunti P. Friedreich’s ataxia: clinical features, pathogenesis and management. British Medical Bulletin. 2017;124:19-30. doi:10.1093/bmb/ldx034.

12. Díez-López C, Comín-Colet J, González-Costello J. Iron overload cardiomyopathy: from diagnosis to management. Current Opinion in Cardiology. 2018;33:334-40. doi:10.1097/HCO.0000000000000511.

13. Reznik EV, Nguyen TL, Stepanova EA, et al. Amyloidosis of the heart: the view of the therapist and cardiologist. Archives of Internal Medicine. 2020;10:430-57. (In Russ.) doi:10.20514/2226-6704-2020-10-6-430-457.

14. Reznik EV, Stepanova EA, Nguyen TL, et al. Retrospective analysis of damage to the cardiovascular system in patients with systemic amyloidosis. Cardiovascular Therapy and Prevention. 2021;20(1):2496. (In Russ.) doi:10.15829/1728-8800-2021-2496.

15. Singh MM, Kumar R, Tewari S, et al. Determining Nt-proBNP Levels with Diastolic Dysfunction in Thalassemia Major Patients. J Pediatr Genet. 2017;6:222-6. doi:10.1055/s-0037-1603193.

16. Child JS, Perloff JK, Bach PM, et al. Cardiac involvement in Friedreich’s ataxia: A clinical study of 75 patients. Journal of the American College of Cardiology. 1986;7:1370-8. doi:10.1016/S0735-1097(86)80159-0.

17. Namdar M, Steffel J, Jetzer S, et al. Value of Electrocardiogram in the Differentiation of Hypertensive Heart Disease, Hypertrophic Cardiomyopathy, Aortic Stenosis, Amyloidosis, and Fabry Disease. The American Journal of Cardiology. 2012;109:587-93. doi:10.1016/j.amjcard.2011.09.052.

18. Serra W, Marziliano N. Role of cardiac imaging in Anderson-Fabry cardiomyopathy. Cardiovasc Ultrasound 2019;17:1. doi:10.1186/s12947-019-0151-5.

19. Fatehi F, Ashrafi MR, Babaee M, et al. Recommendations for Infantile-Onset and Late-Onset Pompe Disease: An Iranian Consensus. Frontiers in Neurology. 2021;12. doi:10.3389/fneur.2021.739931.

20. Albakri A. Deposition diseases cardiomyopathy: A review and pooled analysis of pathophysiology, diagnosis and clinical management. Trends in Research. 2019;2. doi:10.15761/TR.1000147.

21. Rosenfeld LE, Chung MK, Harding CV, et al. Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. Circulation: Arrhythmia and Electrophysiology. 2021;14:e009203. doi:10.1161/CIRCEP.120.009203.

22. Yamada S, Yoshihisa A, Hijioka N, et al. Autonomic dysfunction in cardiac amyloidosis assessed by heart rate variability and heart rate turbulence. Ann Noninvasive Electrocardiol. 2020;25:e12749. doi:10.1111/anec.12749.

23. Azevedo O, Marques N, Reis L, et al. Predictors of Fabry disease in patients with hypertrophic cardiomyopathy: How to guide the diagnostic strategy? American Heart Journal. 2020;226:114-26. doi:10.1016/j.ahj.2020.04.006.

24. Suzuki T, Kanda T, Kubota S, et al. Holter Monitoring as a Noninvasive Indicator of Cardiac Involvement in Sarcoidosis. CHEST. 1994;106:1021-4. doi:10.1378/chest.106.4.1021.

25. Hu K, Liu D, Salinger T, et al. Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function. J Thorac Dis. 2018;10:4966-75. doi:10.21037/jtd.2018.07.56.

26. Perfetto F, Zampieri M, Fumagalli C, et al. Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. Intern Emerg Med. 2022;17:957- 69. doi:10.1007/s11739-022-02958-2.

27. Seydelmann N, Liu D, Krämer J, et al. High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease. Journal of the American Heart Association. 2016;5:e002839. doi:10.1161/JAHA.115.002839.

28. Baba Y, Kubo T, Kawaguchi J, et al. High sensitivity cardiac troponin T is a useful biomarker for predicting prognosis of the patients with sarcoidosis. European Heart Journal. 2020;41:ehaa946.2121. doi:10.1093/ehjci/ehaa946.2121.

29. Takashio S, Yamamuro M, Izumiya Y, et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail. 2017;5:27-35. doi:10.1002/ehf2.12203.

30. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. European Heart Journal. 2018;39:2799-806. doi:10.1093/eurheartj/ehx589.

31. Arvanitis M, Simon S, Chan G, et al. Utility of Retinol Binding Protein 4 (RBP4) concentration for screening of V122I transthyretin cardiac amyloidosis. Amyloid. 2017;24:120-1. doi:10.1080/13506129.2017.1295371.

32. Heaney JLJ, Richter A, Bowcock S, et al. Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels. Haematologica. 2020;105:e169-71. doi:10.3324/haematol.2019.224360.

33. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. NEJM. 2005;352. doi:10.1056/NEJMoa033349.

34. Demoulin N, Aydin S, Gillion V, et al. Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review. American Journal of Kidney Diseases. 2022;79:717- 27. doi:10.1053/j.ajkd.2021.07.018.

35. Azevedo O, Cordeiro F, Gago MF, et al. Fabry Disease and the Heart: A Comprehensive Review. International Journal of Molecular Sciences. 2021;22:4434. doi:10.3390/ijms22094434.

36. Houston BA, Mukherjee M. Cardiac sarcoidosis: clinical manifestations, imaging characteristics, and therapeutic approach. Clin Med Insights Cardiol. 2014;8:31-7. doi:10.4137/CMC.S15713.

37. Gurinova EE, Sukhomyasova AL, Semyachkina AN, et al. Treating a teenager with Morquio A syndrome (mucopolysaccharidosis IV A) with Vimizim. Russian Bulletin of Perinatology and Pediatrics. 2021;66(4):109-17. (In Russ.) doi:10.21508/1027-4065-2021-66-4-109-117.

38. Pagourelias ED, Duchenne J, Mirea O, et al. The Relation of Ejection Fraction and Global Longitudinal Strain in Amyloidosis: Implications for Differential Diagnosis. JACC: Cardiovascular Imaging. 2016;9:1358-9. doi:10.1016/j.jcmg.2015.11.013.

39. Rameeva AS, Rameev VV, Bobkova IN, et al. Leading factors in the progression of cardiac amyloidosis. Rational Pharmacotherapy in Cardiology. 2022;18(2):143-52. (In Russ.) doi:10.20996/1819-6446-2022-04-02.

40. Değirmenci H, Demirelli S, Arısoy A, et al. Myocardial deformation and total atrial conduction time in the prediction of cardiac involvement in patients with pulmonary sarcoidosis. Clin Respir J. 2017;11:68-77. doi:10.1111/crj.12307.

41. Titova AM, Trufanov GE, Fokin VA. T2* Magnetic resonance relaxometry in the quantitative non-invasive evaluation of iron overload in the liver and heart. Translational Medicine 2017;4:37-45. (In Russ.) doi:10.18705/2311-4495-2017-4-5-37-45.

42. Poponina YuS, Poponina TM, Mochula OV, et al. Cardiac sarcoidosis: Difficulties and possibilities of differential diagnosis for acute coronary syndrome without ST segment elevation in real clinical practice. The Siberian Journal of Clinical and Experimental Medicine. 2022;37(1):142-8. (In Russ.) doi:10.29001/2073-8552-2022-37-1-142-148.

43. Fang T, Wang J, Kang Y, et al. The Value of Cardiac Magnetic Resonance Imaging in Identification of Rare Diseases Mimicking Hypertrophic Cardiomyopathy. Journal of Clinical Medicine. 2021;10:3339. doi:10.3390/jcm10153339.

44. Mongeon F-P, Jerosch-Herold M, Coelho-Filho OR, et al. Quantification of Extracellular Matrix Expansion by CMR in Infiltrative Heart Disease. JACC: Cardiovascular Imaging 2012;5:897-907. doi:10.1016/j.jcmg.2012.04.006.

45. Karur GR, Robison S, Iwanochko RM, et al. Use of Myocardial T1 Mapping at 3.0 T to Differentiate Anderson-Fabry Disease from Hypertrophic Cardiomyopathy. Radiology. 2018;288:398-406. doi:10.1148/radiol.2018172613.

46. Crouser ED, Ruden E, Julian MW, et al. Resolution of abnormal cardiac MRI T2 signal following immune suppression for cardiac sarcoidosis. J Investig Med. 2016;64:1148-50. doi:10.1136/jim-2016-000144.

47. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99mTc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. Journal of the American College of Cardiology. 2005;46:1076-84. doi:10.1016/j.jacc.2005.05.073.

48. Bokhari S, Castaño A, Pozniakoff T, et al. 99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circulation: Cardiovascular Imaging. 2013;6:195-201. doi:10.1161/CIRCIMAGING.112.000132.

49. Tower-Rader A, Jaber WA. Multimodality Imaging Assessment of Fabry Disease. Circulation: Cardiovascular Imaging. 2019